BioSpace News Archive

Atom Bioscience, a clinical stage biotechnology company developing new treatments for metabolic and inflammatory diseases, such as gout, is calling for increased understanding of the dangers of chronic gout to help mark Gout Awareness Day, May 22, 2024.

ProKidney Corp. will host a virtual KOL event on Tuesday, May 28, 2024 at 8:00 AM ET, featuring Steven G. Coca, DO, MS and Arnold L. Silva, MD, PhD who will discuss the unmet medical need and current treatment landscape for patients with moderate to severe CKD caused by diabetes as well as the importance of preserving kidney function in this patient population.

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024.

Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announced that it has entered into a clinical collaboration with Merck, to evaluate DF9001, Dragonfly’s EGFR immune engager, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with advanced solid tumors expressing EGFR.

Foundation Medicine, Inc., announced the U.S. launch of FoundationOne®RNA, a tissue-based RNA sequencing test for the detection of cancer-related fusions across 318 genes.

PureTech Health plc noted that its Founded Entity, Vedanta Biosciences announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical study of VE303, which is an orally administered defined bacterial consortium candidate that is being developed for the prevention of recurrent C. difficile infection.

Halozyme Therapeutics, Inc. announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the U.S. FDA for their Biologics License Application for the subcutaneous formulation of Opdivo® co-formulated with ENHANZE®.

Annovis Bio, Inc. announced the publication of a new article focused on the comparison of pharmacokinetic profiles of Posiphen across different species in a peer-reviewed journal Biomolecules as part of the Special Issue: Role of Amyloid Protein in Neurological Diseases.

Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fifth patient in its ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

Reese Pharmaceutical, a privately held manufacturer of over-the-counter branded and private label products announced ColoTest®, its new Fecal Immunochemical Test for colon cancer screening, is now available at 3,700 Walmart locations across the U.S.